Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

This was the stock's second consecutive day of losses.

Shares of Novavax Inc. NVAX shed 1.52% to $7.15 Wednesday, on what proved to be an all-around mixed trading session for the ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

The FDA is adopting a new regulatory framework that will change the criteria for approval of COVID-19 vaccines.

Life science companies developing bird flu vaccines and antivirals are gaining attention as the avian influenza subtype H5N1 ...

The FDA approved Moderna’s lower-dose COVID-19 vaccine, but only for individuals aged 65 years or older and people aged 12 to ...

The FDA is implementing stricter guidance for the approval of COVID-19 vaccines, according to a paper published in The New England Journal of Medicine.

The FDA approved Moderna’s new Covid-19 vaccine late Friday, though it placed restrictions on its use that the company’s ...

Moderna Inc. gained U.S. approval for a new COVID vaccine for a narrower group of people, in the latest sign that regulators ...

Despite uncertainties arising from new FDA policies around COVID-19 vaccines, Moderna has cleared the agency's desk with its ...